Key Points
- Alaleh Nouri, EVP of PROCEPT BioRobotics, sold 3,243 shares on March 10 at an average price of $25.65 for $83,182.95, trimming her stake by 2.84% to 111,021 shares; she also sold 6,892 shares on March 6 at $23.70.
- PROCEPT reported Q4 EPS of -$0.53 (vs. -$0.32 expected) and revenue of $76.38M (vs. $93.7M expected), though revenue was up 11.9% year-over-year.
- Analysts have cut price targets recently and the consensus rating is a “Hold” with an average target of $40.82; the stock has a market cap of about $1.53 billion and a one-year range of $19.35–$66.85.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) EVP Alaleh Nouri sold 3,243 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $25.65, for a total value of $83,182.95. Following the transaction, the executive vice president owned 111,021 shares in the company, valued at approximately $2,847,688.65. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Alaleh Nouri also recently made the following trade(s):
- On Friday, March 6th, Alaleh Nouri sold 6,892 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $23.70, for a total value of $163,340.40.
PROCEPT BioRobotics Price Performance
NASDAQ:PRCT traded up $1.00 during mid-day trading on Friday, reaching $27.12. 616,893 shares of the stock were exchanged, compared to its average volume of 1,682,705. PROCEPT BioRobotics Corporation has a 1-year low of $19.35 and a 1-year high of $66.85. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14. The business has a fifty day moving average price of $28.78 and a 200 day moving average price of $32.63. The firm has a market capitalization of $1.53 billion, a PE ratio of -15.81 and a beta of 1.02.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The company had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. PROCEPT BioRobotics's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.35) EPS. Research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.
Institutional Trading of PROCEPT BioRobotics
Hedge funds and other institutional investors have recently modified their holdings of the company. Advisory Services Network LLC lifted its holdings in shares of PROCEPT BioRobotics by 1.3% during the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company's stock valued at $1,158,000 after buying an additional 250 shares during the last quarter. Vega Investment Solutions boosted its holdings in PROCEPT BioRobotics by 52.0% in the second quarter. Vega Investment Solutions now owns 775 shares of the company's stock worth $45,000 after purchasing an additional 265 shares in the last quarter. Frank Rimerman Advisors LLC lifted its position in shares of PROCEPT BioRobotics by 0.3% in the third quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company's stock worth $4,368,000 after buying an additional 307 shares during the last quarter. RiverPark Advisors LLC increased its holdings in shares of PROCEPT BioRobotics by 22.5% during the 2nd quarter. RiverPark Advisors LLC now owns 1,761 shares of the company's stock valued at $101,000 after acquiring an additional 324 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in PROCEPT BioRobotics by 20.3% in the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company's stock worth $115,000 after purchasing an additional 337 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms have recently issued reports on PRCT. Piper Sandler cut their price target on shares of PROCEPT BioRobotics from $50.00 to $28.00 and set an "overweight" rating on the stock in a report on Thursday, February 26th. Morgan Stanley cut their target price on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an "overweight" rating on the stock in a research note on Tuesday, December 2nd. TD Cowen reduced their target price on PROCEPT BioRobotics from $50.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, February 26th. Truist Financial decreased their target price on PROCEPT BioRobotics from $47.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, February 27th. Finally, Wells Fargo & Company lowered their price target on PROCEPT BioRobotics from $51.00 to $34.00 and set an "overweight" rating on the stock in a report on Thursday, February 26th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $40.82.
Read Our Latest Research Report on PRCT
About PROCEPT BioRobotics
(
Get Free Report)
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
